TGF-β signaling in tumor suppression and cancer progression

被引:1935
作者
Derynck, R [1 ]
Akhurst, RJ
Balmain, A
机构
[1] Univ Calif San Francisco, Dept Growth & Dev, Cell Biol Program, San Francisco, CA 94143 USA
[2] Univ Calif San Francisco, Dept Anat, Program Dev Biol, San Francisco, CA 94143 USA
[3] Univ Calif San Francisco, Mt Zion Canc Res Inst, San Francisco, CA 94143 USA
[4] Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA
基金
美国国家卫生研究院;
关键词
D O I
10.1038/ng1001-117
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Epithelial and hematopoietic cells have a high turnover and their progenitor cells divide continuously, making them prime targets for genetic and epigenetic changes that lead to cell transformation and tumorigenesis. The consequent changes in cell behavior and responsiveness result not only from genetic alterations such as activation of oncogenes or inactivation of tumor suppressor genes, but also from altered production of, or responsiveness to, stimulatory or inhibitory growth and differentiation factors. Among these, transforming growth factor beta (TGF-beta) and its signaling effectors act as key determinants of carcinoma cell behavior. The autocrine and paracrine effects of TGF-beta on tumor cells and the tumor micro-environment exert both positive and negative influences on cancer development. Accordingly, the TGF-beta signaling pathway has been considered as both a tumor suppressor pathway and a promoter of tumor progression and invasion. Here we evaluate the role of TGF-beta in tumor development and attempt to reconcile the positive and negative effects of TGF-beta in carcinogenesis.
引用
收藏
页码:117 / 129
页数:13
相关论文
共 326 条
[1]   Induction of inhibitory Smad6 and Smad7 mRNA by TGF-β family members [J].
Afrakhte, M ;
Morén, A ;
Jossan, S ;
Itoh, S ;
Westermark, B ;
Heldin, CH ;
Heldin, NE ;
ten Dijke, P .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1998, 249 (02) :505-511
[2]   FKBP12, the 12-kDa FK506-binding protein, is a physiologic regulator of the cell cycle [J].
Aghdasi, B ;
Ye, KQ ;
Resnick, A ;
Huang, A ;
Ha, HC ;
Guo, X ;
Dawson, TM ;
Dawson, VL ;
Snyder, SH .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (05) :2425-2430
[3]   c-Ski acts as a transcriptional co-repressor in transforming growth factor-β signaling through interaction with Smads [J].
Akiyoshi, S ;
Inoue, H ;
Hanai, J ;
Kusanagi, K ;
Nemoto, N ;
Miyazono, K ;
Kawabata, M .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (49) :35269-35277
[4]   OVEREXPRESSION OF THE C-MYC ONCOPROTEIN BLOCKS THE GROWTH-INHIBITORY RESPONSE BUT IS REQUIRED FOR THE MITOGENIC EFFECTS OF TRANSFORMING GROWTH-FACTOR-BETA-1 [J].
ALEXANDROW, MG ;
KAWABATA, M ;
AAKRE, M ;
MOSES, HL .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1995, 92 (08) :3239-3243
[5]   TGF-β-induced repression of CBFA1 by Smad3 decreases cbfa1 and osteocalcin expression and inhibits osteoblast differentiation [J].
Alliston, T ;
Choy, L ;
Ducy, P ;
Karsenty, G ;
Derynck, R .
EMBO JOURNAL, 2001, 20 (09) :2254-2272
[6]   Consistent loss of functional transforming growth factor β receptor expression in murine plasmacytomas [J].
Amoroso, SR ;
Huang, NH ;
Roberts, AB ;
Potter, M ;
Letterio, JJ .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (01) :189-194
[7]  
Ananth S, 1999, CANCER RES, V59, P2210
[8]  
Andreasen PA, 1997, INT J CANCER, V72, P1, DOI 10.1002/(SICI)1097-0215(19970703)72:1<1::AID-IJC1>3.0.CO
[9]  
2-Z
[10]   Reversal of tamoxifen resistance of human breast carcinomas in vivo by neutralizing antibodies to transforming growth factor-β [J].
Arteaga, CL ;
Koli, KM ;
Dugger, TC ;
Clarke, R .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1999, 91 (01) :46-53